Campbell Newman Asset Management’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $28.6M | Sell |
31,129
-10,424
| -25% | -$10.6M | 2.32% | 20 |
|
|
2025
Q4 | $44.7M | Buy |
41,553
+129
| +0.3% | +$123K | 3.27% | 6 |
|
|
2025
Q3 | $31.6M | Buy |
41,424
+429
| +1% | +$319K | 2.31% | 20 |
|
|
2025
Q2 | $32M | Sell |
40,995
-14,314
| -26% | -$11.1M | 2.55% | 15 |
|
|
2025
Q1 | $45.7M | Sell |
55,309
-4,401
| -7% | -$3.66M | 3.88% | 4 |
|
|
2024
Q4 | $46.1M | Sell |
59,710
-2,617
| -4% | -$2.17M | 3.72% | 4 |
|
|
2024
Q3 | $55.2M | Sell |
62,327
-75
| -0.1% | -$67.4K | 4.15% | 4 |
|
|
2024
Q2 | $56.5M | Sell |
62,402
-1,635
| -3% | -$1.31M | 4.52% | 5 |
|
|
2024
Q1 | $49.8M | Sell |
64,037
-393
| -0.6% | -$280K | 4.04% | 5 |
|
|
2023
Q4 | $37.6M | Sell |
64,430
-623
| -1% | -$364K | 3.24% | 7 |
|
|
2023
Q3 | $34.9M | Sell |
65,053
-23,294
| -26% | -$12M | 3.31% | 7 |
|
|
2023
Q2 | $41.4M | Buy |
88,347
+517
| +0.6% | +$217K | 3.71% | 6 |
|
|
2023
Q1 | $30.2M | Sell |
87,830
-353
| -0.4% | -$119K | 2.93% | 11 |
|
|
2022
Q4 | $32.3M | Buy |
88,183
+531
| +0.6% | +$188K | 3.21% | 9 |
|
|
2022
Q3 | $28.3M | Sell |
87,652
-276
| -0.3% | -$87.4K | 3.19% | 10 |
|
|
2022
Q2 | $28.5M | Buy |
87,928
+4,555
| +5% | +$1.37M | 3.01% | 10 |
|
|
2022
Q1 | $23.9M | Sell |
83,373
-244
| -0.3% | -$62.8K | 2.3% | 20 |
|
|
2021
Q4 | $23.1M | Buy |
83,617
+55
| +0.1% | +$13.9K | 2.06% | 22 |
|
|
2021
Q3 | $19.3M | Sell |
83,562
-17,083
| -17% | -$4.22M | 1.97% | 21 |
|
|
2021
Q2 | $23.1M | Buy |
100,645
+403
| +0.4% | +$81K | 2.27% | 18 |
|
|
2021
Q1 | $18.7M | Buy |
100,242
+1,406
| +1% | +$275K | 1.97% | 20 |
|
|
2020
Q4 | $16.7M | Buy |
98,836
+1,886
| +2% | +$282K | 1.89% | 22 |
|
|
2020
Q3 | $14.4M | Buy |
96,950
+170
| +0.2% | +$26.3K | 1.84% | 23 |
|
|
2020
Q2 | $15.9M | Buy |
96,780
+1,424
| +1% | +$219K | 2.19% | 19 |
|
|
2020
Q1 | $13.2M | Buy |
95,356
+38
| +0% | +$5.22K | 2.27% | 16 |
|
|
2019
Q4 | $12.5M | Buy |
95,318
+310
| +0.3% | +$35.9K | 1.69% | 28 |
|
|
2019
Q3 | $10.6M | Buy |
95,008
+2,125
| +2% | +$237K | 1.52% | 29 |
|
|
2019
Q2 | $10.3M | Buy |
92,883
+1,767
| +2% | +$208K | 1.5% | 30 |
|
|
2019
Q1 | $11.8M | Buy |
91,116
+64,800
| +246% | +$7.88M | 1.83% | 27 |
|
|
2018
Q4 | $3.04M | Hold |
26,316
| – | – | 0.53% | 38 |
|
|
2018
Q3 | $2.82M | Hold |
26,316
| – | – | 0.41% | 41 |
|
|
2018
Q2 | $2.25M | Hold |
26,316
| – | – | 0.35% | 44 |
|
|
2018
Q1 | $2.04M | Hold |
26,316
| – | – | 0.34% | 46 |
|
|
2017
Q4 | $2.22M | Hold |
26,316
| – | – | 0.37% | 44 |
|
|
2017
Q3 | $2.25M | Hold |
26,316
| – | – | 0.4% | 44 |
|
|
2017
Q2 | $2.17M | Hold |
26,316
| – | – | 0.39% | 44 |
|
|
2017
Q1 | $2.21M | Hold |
26,316
| – | – | 0.41% | 41 |
|
|
2016
Q4 | $1.94M | Hold |
26,316
| – | – | 0.37% | 43 |
|
|
2016
Q3 | $2.11M | Hold |
26,316
| – | – | 0.37% | 44 |
|
|
2016
Q2 | $2.07M | Buy |
+26,316
| New | +$1.98M | 0.38% | 44 |
|
Other funds holding LLY
VCM
VPM
Campbell Newman Asset Management's LLY Position: Q1 2026 in Review
Campbell Newman Asset Management reduced its Eli Lilly (LLY) stake by 25% in Q1 2026, selling an estimated $10.6M and leaving 31,129 shares worth $28.6M. The position accounts for 2.32% of the portfolio, ranked #20.
Campbell Newman Asset Management first reported a position in LLY in Q2 2016 and has held it in 40 quarters since. The position peaked at $56.5M in Q2 2024. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Campbell Newman Asset Management held 31,129 shares of Eli Lilly worth $28.6M as of Q1 2026.
- Campbell Newman Asset Management sold 10,424 Eli Lilly shares in Q1 2026, an estimated $10.6M.
- Eli Lilly made up 2.32% of Campbell Newman Asset Management's portfolio in Q1 2026, its #20 holding.
- Campbell Newman Asset Management first reported a position in Eli Lilly in Q2 2016 and has held it in 40 quarters since.
- Campbell Newman Asset Management's Eli Lilly position peaked at $56.5M in Q2 2024.
- 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Campbell Newman Asset Management's 13F filing for Q1 2026, filed 16 Apr 2026.